Activation of the JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis.
about
Oxidative Stress Signaling in Alzheimers DiseaseUp-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's diseaseAmyloid-β and Astrocytes Interplay in Amyloid-β Related DisordersLithium inhibits Abeta-induced stress in endoplasmic reticulum of rabbit hippocampus but does not prevent oxidative damage and tau phosphorylation.Kinase Inhibitor Screening Identifies Cyclin-Dependent Kinases and Glycogen Synthase Kinase 3 as Potential Modulators of TDP-43 Cytosolic Accumulation during Cell Stress.Conformational changes and cleavage of tau in Pick bodies parallel the early processing of tau found in Alzheimer pathology.The p38alpha mitogen-activated protein kinase as a central nervous system drug discovery target.Targeting protein kinases in central nervous system disordersJNK3 involvement in nerve cell apoptosis and neurofunctional recovery after traumatic brain injuryC-Jun N-terminal kinase controls TDP-43 accumulation in stress granules induced by oxidative stressKinesin-1 transport reductions enhance human tau hyperphosphorylation, aggregation and neurodegeneration in animal models of tauopathiesRole of p38 and p44/42 mitogen-activated protein kinases in microglia.Dysregulation of mitogen-activated protein kinase signaling pathways in simian immunodeficiency virus encephalitis.Oxidative stress, cell cycle, and neurodegeneration.Genetically augmenting Abeta42 levels in skeletal muscle exacerbates inclusion body myositis-like pathology and motor deficits in transgenic mice.Activation of the ERK and JNK signaling pathways caused by neuron-specific inhibition of PP2A in transgenic mice.Neurodegenerative tauopathy in the worm.Gene-environment interplay in neurogenesis and neurodegeneration.Tau Hyperphosphorylation and Oxidative Stress, a Critical Vicious Circle in Neurodegenerative Tauopathies?5-Lipoxygenase gene transfer worsens memory, amyloid, and tau brain pathologies in a mouse model of Alzheimer disease.The brain as a target for inflammatory processes and neuroprotective strategies.The influence of 5-lipoxygenase on Alzheimer's disease-related tau pathology: in vivo and in vitro evidence.Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease.Brain site-specific proteome changes in aging-related dementia.Phosphorylated tau: toxic, protective, or none of the aboveThe 12-15-lipoxygenase is a modulator of Alzheimer's-related tau pathology in vivoAxonal stress kinase activation and tau misbehavior induced by kinesin-1 transport defects.Redox control of the cell cycle in health and disease.Rational therapeutic approaches to progressive supranuclear palsy.Screening of treatment targets for Alzheimer's disease from the molecular mechanisms of impairment by β-amyloid aggregation and tau hyperphosphorylation.A novel perspective on tau in Alzheimer's disease.Protein phosphorylation in neurodegeneration: friend or foe?Cell-cycle markers in a transgenic mouse model of human tauopathy: increased levels of cyclin-dependent kinase inhibitors p21Cip1 and p27Kip1.Pharmacologic blockade of 12/15-lipoxygenase ameliorates memory deficits, Aβ and tau neuropathology in the triple-transgenic mice.An unbiased approach to identifying tau kinases that phosphorylate tau at sites associated with Alzheimer disease.Stable mutated tau441 transfected SH-SY5Y cells as screening tool for Alzheimer's disease drug candidates.MAPK-activated protein kinase 2 deficiency in microglia inhibits pro-inflammatory mediator release and resultant neurotoxicity. Relevance to neuroinflammation in a transgenic mouse model of Alzheimer disease.Effects of melatonin on wortmannin-induced tau hyperphosphorylation.Differential expression of phosphorylated translation initiation factor 2 alpha in Alzheimer's disease and Creutzfeldt-Jakob's disease.Activated p38MAPK is a novel component of the intracellular inclusions found in human amyotrophic lateral sclerosis and mutant SOD1 transgenic mice.
P2860
Q22241327-3316BC1E-5C22-42CB-B896-06F8C73DE466Q24685592-F937FB0C-4D05-4113-9742-C8AE0364CC28Q26766934-5B203C7B-5763-4A5B-8EE5-0E66046EE669Q30310554-7B76D49A-7392-4A1E-A923-32BAE97AEF56Q31122876-33984535-A686-4E37-B0DC-B5FAB3367B96Q33304384-DDDBE7B7-96BE-47D2-B663-56DFE643A499Q33393902-E2D92952-51F5-4E17-9F33-BAA8693FAF2FQ33671660-320BA92A-82D2-4D65-935A-DE93F1804211Q33937827-E9884B06-39BD-49D2-95C8-D97562AB994CQ34206209-1E16660B-FA72-43E4-A9EF-C99F6375B0ADQ34211969-588D4944-2368-40BC-AAB2-1795CE020B00Q34963708-500708C7-5214-43E7-8963-0989A63A3865Q35083375-E813890E-8C43-4869-9AE9-9EB7EA3C3615Q35086148-00296C43-32A5-4CB1-A03C-516E86512C0EQ35088423-AC1B5FA7-BAED-406E-9C33-3186D96BB386Q35791948-14747A46-2B9F-45B4-B5CE-51EC6412B7A4Q35812805-4398280B-7FC8-4D01-B59C-DC4388AB23E0Q36003798-C93EC112-7387-44D4-AB56-602238211AECQ36241505-89EA288E-B40E-477C-9D40-EF60657C9F14Q36299503-2FA4D3AB-DE94-403D-B68C-1F067EF3A882Q37031200-D69010CD-BAE0-4F7D-A668-2C0F50DF31F0Q37053817-236C81A3-349B-49FF-90A7-56B55A4CC05FQ37190465-6ECADE10-7139-47EC-8F24-BA3CDDDAF56FQ37212178-B7578288-14D1-4676-8FBC-0793205B0063Q37238262-7DAB669C-9EF9-4031-BDF9-7EE8EC0F27F5Q37337281-2543036E-3F3C-469D-AAC8-D404A39FD023Q37361338-52CC2920-BA71-4749-B006-D8CEDD8AF7D6Q37510851-6B8D87BE-FF01-4397-B3AB-C2E15950C8C1Q37753509-C329AEA5-608E-4CE9-816D-63739DFB4398Q37832656-DD0784CF-E712-4FA0-95ED-12F97656D79EQ37878513-C276C57A-A04B-4E32-92BA-7EC21378A9BCQ38214594-6D0D9083-B818-4E1F-8D33-5D95BFB1E8D3Q38622669-F67134B8-3394-40FD-828A-D7ED87F85BA3Q38922994-44856643-F254-4063-B375-0A39465E4524Q39135430-9341E309-564C-4945-BA04-6CAB84A7EB2AQ39393192-47C32F7A-C403-45E9-B8DA-0EB444E2BF9DQ40267937-11E1E4E3-38AC-4566-A02A-8AA70D613ACBQ40432890-6239465F-F463-4D6C-AAF5-ADD092530F16Q44224817-B12FF4E0-B02D-4740-AC65-691DBBD5FEA5Q44780025-7FC72F1E-9885-4645-B2C8-96CC8E782E0E
P2860
Activation of the JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Activation of the JNK/p38 path ...... rylation but not to apoptosis.
@en
Activation of the JNK/p38 path ...... rylation but not to apoptosis.
@nl
type
label
Activation of the JNK/p38 path ...... rylation but not to apoptosis.
@en
Activation of the JNK/p38 path ...... rylation but not to apoptosis.
@nl
prefLabel
Activation of the JNK/p38 path ...... rylation but not to apoptosis.
@en
Activation of the JNK/p38 path ...... rylation but not to apoptosis.
@nl
P2093
P2860
P356
P1476
Activation of the JNK/p38 path ...... rylation but not to apoptosis.
@en
P2093
Delisle MB
Srinivasan AN
P2860
P304
P356
10.1093/JNEN/60.12.1190
P577
2001-12-01T00:00:00Z